ReviewCureus2025
Hypertension and Cerebral Small Vessel Disease: A Review of the Pathophysiology, Progression, and Prevention.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- DCE-MRI study on regional and Fazekas-stratified heterogeneity of blood-brain barrier leakage in white matter hyperintensities and related risk factors.Quantitative imaging in medicine and surgery · 2026Article
- Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Cognitive Decline in Chronic Coronary Syndrome: Associations with Vascular, Cardiac, and Neuropsychological Parameters.Medicina (Kaunas, Lithuania) · 2026Observational
- The Molecular Neurobiology of NG2-Expressing Glial Cells in Cerebral Small Vessel Disease Pathogenesis.Molecular neurobiology · 2026Review
- Distinct phenotype of isolated dizziness stroke: association with cerebellar infarctions and elevated LDL-C.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hypertension often leads to cerebral small vessel disease (CSVD), a condition marked by cumulative damage to the small arteries and arterioles within the brain. Radiologically, CSVD is associated with white matter hyperintensities, lacunar infarcts, and cerebral microbleeds. Clinically, it often presents with cognitive dysfunction, gait abnormalities, and an elevated risk of stroke. Histopathological changes in CSVD due to hypertension include thickening of arteriolar walls, breakdown of the blood-brain barrier, and chronic cerebral ischemia. CSVD is commonly seen in patients with long-standing hypertension, but it is not systematically screened for and is often undiagnosed. Few risk stratification models are incorporated in the outpatient management of hypertensive patients. The primary management strategy for CSVD is stringent control of blood pressure, but the precise target levels and preferred antihypertensive medications to prevent disease progression are not well-defined. Early identification of patients at risk for developing CSVD with ambulatory blood pressure monitoring, cognitive assessment, and brain imaging before the development of functional impairment may be a strategy to consider. In the future, we anticipate a more interdisciplinary care model for CSVD to help delineate the therapeutic window for treatment. Longitudinal studies that evaluate the inclusion of CSVD in the management of hypertension in standard practice will be important to incorporate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.